0001047469-17-002433 Sample Contracts
STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN AKCEA THERAPEUTICS, INC. AND NOVARTIS PHARMA AGStrategic Collaboration, Option and License Agreement • April 10th, 2017 • Akcea Therapeutics, Inc. • Pharmaceutical preparations • New York
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 5th day of January, 2017 (the “Execution Date”) by and between AKCEA THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea’s Affiliates (“Akcea”), and NOVARTIS PHARMA AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (“Novartis”). Novartis and Akcea each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (“Ionis”) and therefore Akcea and Ionis are Affiliates.
Standard Contracts
INDEMNITY AGREEMENTIndemnity Agreement • April 10th, 2017 • Akcea Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into this [ ] day of [ ], [201 ] by and between Akcea Therapeutics, Inc., a Delaware corporation (the “Corporation”), and [ ] (“Agent”).
